TY - JOUR
T1 - Oseltamivir dosing in premature infants
AU - McPherson, Christopher
AU - Warner, Barbara
AU - Hunstad, David A.
AU - Elward, Alexis
AU - Acosta, Edward P.
N1 - Funding Information:
Financial support. This work was supported by St. Louis Children’s Hospital, Washington University School of Medicine, and Genentech, Inc. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
PY - 2012/9/15
Y1 - 2012/9/15
N2 - We conducted a 2-sample pharmacokinetic study of oseltamivir in 12 premature infants. Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n = 8) resulted in oseltamivir carboxylate exposure comparable to previously published pediatric data, which helps prospectively validate this regimen. Oseltamivir 3 mg/kg/dose once daily in premature infants >38 weeks postmenstrual age (born prematurely but chronologically past term, n = 4) resulted in similar oseltamivir and oseltamivir carboxylate exposure. Although these results suggest persistence of immature renal function in this subgroup, further pharmacokinetic/pharmacodynamic description is required to confirm the appropriateness of this regimen.
AB - We conducted a 2-sample pharmacokinetic study of oseltamivir in 12 premature infants. Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n = 8) resulted in oseltamivir carboxylate exposure comparable to previously published pediatric data, which helps prospectively validate this regimen. Oseltamivir 3 mg/kg/dose once daily in premature infants >38 weeks postmenstrual age (born prematurely but chronologically past term, n = 4) resulted in similar oseltamivir and oseltamivir carboxylate exposure. Although these results suggest persistence of immature renal function in this subgroup, further pharmacokinetic/pharmacodynamic description is required to confirm the appropriateness of this regimen.
UR - http://www.scopus.com/inward/record.url?scp=84865764387&partnerID=8YFLogxK
U2 - 10.1093/infdis/jis471
DO - 10.1093/infdis/jis471
M3 - Article
C2 - 22807525
AN - SCOPUS:84865764387
VL - 206
SP - 847
EP - 850
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 6
ER -